Independent 5-year pharmaceutical and healthcare industry forecasts for Iran.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Iranian pharmaceutical and healthcare industry.
Competitive intelligence, Iranian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Iranian market.
The Iran Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Its Iran Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Iranian pharmaceutical and healthcare industry.
Key Benefits of Report
Benchmark Its Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Iran to test other views – a key input for successful budgeting and strategic business planning in the Iranian pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Iranian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Iran.
Exploit The Latest Competitive Iranian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Iran.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Its forecast analysis, and taken together with Its Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
It 5-Year Industry Forecast
5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism;
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke It economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
It 5-Year Macroeconomic Forecasts
It forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. It profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
Executive Summary
The Sector At A Glance
Key Insights On The Pharmaceutical Sector Of Iran
Iran has a large and predominantly young population, which should be instrumental in driving the expansion of the pharmaceutical market over the coming years. It expects the value of the drug market to reach US$1.93bn by 2010.
Meanwhile, It has also recently revised its trade forecasts for Iran after the Ministry of Health released new data covering this area. With the government looking to privatise the drug import sector, It expects imports to reach US$658.8mn in 2010. Meanwhile, investment in production facilities has been instrumental in the development of drug exports. It forecasts that exports will hit US$135mn by 2010, still relatively low by international standards, but representing an almost doubling of current levels.
Two markets that are increasing in importance are Iraq and Afghanistan as these countries’ economies begin to slowly recover from the effects of war. Afghanistan is currently Iran’s largest drug export partner. Local player Iran Pharmaceutical Development and Investment Company (IPDC) has yet to see sales return to pre-war levels. Future export growth will concentrate on the former Soviet sates in Central Asia, and the potentially lucrative African market. Meanwhile, Oman and Iran are planning to increase their co-operation in the field of healthcare, which could see a rise in exports from Iran to Oman.
Drug prices, which are still among the lowest in the region, are rising as domestic companies seek to boost revenue. Meanwhile, if the government cuts fuel subsidies, domestic producers may face higher operating costs, which could stimulate a round of price increases, although the authorities will resist this.
Its adjusted Business Environment Rankings for the Middle East and Africa (MEA) reveal that Iran is in 12th place, ahead only of Nigeria and Zimbabwe. This is primarily due to political and economic uncertainty in the country, coupled with poor intellectual property standards. However, Iran’s market is experiencing robust growth, although the dominant position of local manufacturing provides a substantial obstacle to investment.
For more information, Please visit :
http://www.bharatbook.com/
